B. Scheel

发表

Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

H. Rammensee, C. Garbe, S. Pascolo, 2008, Journal of immunotherapy.

Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

H. Rammensee, C. Garbe, G. Pawelec, 2009, Journal of immunotherapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

S. Koch, R. Cathomas, M. Fotin‐Mleczek, 2014, BMC Cancer.

Human peripheral blood monuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro

H. Rammensee, J. Probst, G. Jung, 2005, Cellular and Molecular Life Sciences CMLS.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

D. Atanackovic, Michael Thomas, S. Koch, 2019, Cancer Immunology, Immunotherapy.

Immunostimulating capacities of stabilized RNA molecules

H. Rammensee, H. Schild, H. Wagner, 2004, European journal of immunology.

Genetic Vaccines and Therapy

H. Rammensee, J. Probst, G. Jung, 2006 .

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.

H. Rammensee, O. Schoor, C. Garbe, 2005, Genetic vaccines and therapy.

Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA

H. Rammensee, M. Weller, L. Stitz, 2006, European journal of immunology.

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

H. Rammensee, B. Pichler, J. Probst, 2007, Gene Therapy.

Genetic Vaccines and Therapy

H. Rammensee, J. Probst, G. Jung, 2006 .

A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

S. Voss, M. Fotin‐Mleczek, Patrick Baumhof, 2015, International journal of cancer.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

S. Koch, R. Cathomas, M. Fotin‐Mleczek, 2019, Journal of Immunotherapy for Cancer.

Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA

H. Rammensee, D. Jarrossay, H. Wagner, 2005, European journal of immunology.

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

K. Miller, W. Schultze‐Seemann, A. Stenzl, 2015, Journal of Immunotherapy for Cancer.

Co-Transfection of Messenger RNA and siRNA as a Method to Study the Efficiency of siRNA

J. Probst, K. Ghoreschi, S. Pascolo, 2005, Nucleosides, nucleotides & nucleic acids.

A novel, disruptive vaccination technology

T. Schlake, S. Koch, A. Thess, 2013, Human vaccines & immunotherapeutics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines

H. Rammensee, J. Probst, G. Jung, 2004, Cellular and Molecular Life Sciences CMLS.

Human peripheral blood monuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro

H. Rammensee, J. Probst, G. Jung, 2005, Cellular and Molecular Life Sciences CMLS.

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

H. Rammensee, B. Pichler, J. Probst, 2009, Gene Therapy.

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy

O. Kohlbacher, J. Billingsley, S. Koch, 2016, Oncoimmunology.

Messenger RNA vaccination and B-cell responses in NSCLC patients.

D. Atanackovic, S. Koch, F. Mayer, 2012 .

Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial.

D. Atanackovic, R. Bals, F. Mayer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.

U. Steiner, K. Miller, W. Schultze‐Seemann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses

A. Stenzl, G. Rippin, K. Kallen, 2013, Journal of Immunotherapy for Cancer.

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas

O. Schoor, J. Probst, S. Pascolo, 2005 .

Genetic Vaccines and Therapy Production and Characterization of Amplified Tumor-derived Crna Libraries to Be Used as Vaccines against Metastatic Melanomas